Granules India Hyderabad facility receives 5 USFDA observations

Granules India arm gets 5 USFDA observations for Hyderabad facility. The pharma company's subsidiary received 5 observations from the US FDA during inspection of its Hyderabad manufacturing facility. These observations typically require corrective action plans but are not critical deficiencies. The company will need to address these compliance issues to maintain its US market certifications.

📊 STOCKS: GRANULES | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Compliance